Sanofi (SNY) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↑
10.91
-8% vs avg
5yr avg: 11.92
30Y Low7.4·High17.0
P/FCF
↓
10.13
↓-35% vs avg
5yr avg: 15.53
30Y Low10.3·High162.7
P/B Ratio
↓
1.27
↓-24% vs avg
5yr avg: 1.66
30Y Low1.6·High8.4
ROE
↑
10.4%
↓+14% vs avg
5yr avg: 9.2%
30Y Low5%·High33%
Debt/EBITDA
↑
2.28
↑+25% vs avg
5yr avg: 1.83
30Y Low0.1·High3.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SNY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sanofi trades at 18.4x earnings, 12% below its 5-year average of 20.9x, sitting at the 25th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a discount of 17%. On a free-cash-flow basis, the stock trades at 10.1x P/FCF, 35% below the 5-year average of 15.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $105.7B | $118.3B | $120.7B | $125.0B | $121.3B | $125.5B | $121.8B | $125.5B | $108.3B | $108.1B | $104.1B |
| Enterprise Value | $122.3B | $132.4B | $131.2B | $134.9B | $129.7B | $137.8B | $131.6B | $141.7B | $126.0B | $113.4B | $112.4B |
| P/E Ratio → | 18.37 | 23.87 | 22.02 | 23.13 | 15.23 | 20.12 | 9.90 | 44.04 | 25.09 | 12.80 | 22.10 |
| P/S Ratio | 1.93 | 2.53 | 2.73 | 3.00 | 2.99 | 3.20 | 3.26 | 3.33 | 3.03 | 2.98 | 3.00 |
| P/B Ratio | 1.27 | 1.65 | 1.55 | 1.68 | 1.61 | 1.82 | 1.93 | 2.12 | 1.83 | 1.86 | 1.80 |
| P/FCF | 10.13 | 13.30 | 20.51 | 14.46 | 14.57 | 14.80 | 22.84 | 21.17 | 30.33 | 19.93 | 18.08 |
| P/OCF | 8.38 | 11.00 | 13.29 | 12.18 | 11.52 | 11.93 | 16.35 | 16.20 | 19.52 | 14.65 | 13.28 |
P/E links to full P/E history page with 30-year chart
SNY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Sanofi's enterprise value stands at 10.9x EBITDA, 8% below its 5-year average of 11.9x. The Healthcare sector median is 14.1x, placing the stock at a 23% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.83 | 2.96 | 3.24 | 3.20 | 3.52 | 3.52 | 3.77 | 3.53 | 3.13 | 3.24 |
| EV / EBITDA | 10.91 | 13.86 | 12.10 | 11.85 | 9.78 | 12.01 | 7.40 | 13.50 | 14.07 | 11.95 | 11.43 |
| EV / EBIT | 16.43 | 13.98 | 17.61 | 19.39 | 12.47 | 16.83 | 9.26 | 44.04 | 25.71 | 19.05 | 17.03 |
| EV / FCF | — | 14.89 | 22.29 | 15.62 | 15.58 | 16.25 | 24.66 | 23.90 | 35.29 | 20.91 | 19.52 |
SNY Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sanofi earns an operating margin of 13.6%. Operating margins have compressed from 16.7% to 13.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 10.4% is modest. ROIC of 5.5% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.3% | 72.3% | 70.2% | 69.7% | 70.7% | 68.7% | 67.5% | 68.2% | 67.9% | 67.9% | 69.2% |
| Operating Margin | 13.6% | 13.6% | 16.4% | 16.7% | 25.1% | 20.7% | 37.8% | 8.1% | 13.1% | 16.0% | 18.8% |
| Net Profit Margin | 16.7% | 16.7% | 12.6% | 13.0% | 20.6% | 15.9% | 32.9% | 7.3% | 12.1% | 23.2% | 13.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.4% | 10.4% | 7.3% | 7.2% | 11.6% | 9.4% | 20.1% | 4.7% | 7.3% | 14.5% | 8.1% |
| ROA | 6.0% | 6.0% | 4.3% | 4.3% | 6.8% | 5.3% | 10.8% | 2.5% | 4.1% | 8.2% | 4.5% |
| ROIC | 5.5% | 5.5% | 6.3% | 6.2% | 9.2% | 7.9% | 14.3% | 3.0% | 5.0% | 6.7% | 7.4% |
| ROCE | 6.3% | 6.3% | 7.0% | 6.8% | 10.1% | 8.4% | 15.1% | 3.3% | 5.2% | 6.7% | 7.5% |
SNY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Sanofi carries a Debt/EBITDA ratio of 2.3x, which is manageable (27% below the sector average of 3.1x). Net debt stands at $14.1B ($21.8B total debt minus $7.7B cash). Interest coverage of 17.5x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.30 | 0.30 | 0.23 | 0.25 | 0.28 | 0.32 | 0.37 | 0.44 | 0.42 | 0.27 | 0.32 |
| Debt / EBITDA | 2.28 | 2.28 | 1.65 | 1.64 | 1.60 | 1.95 | 1.33 | 2.47 | 2.75 | 1.64 | 1.89 |
| Net Debt / Equity | — | 0.20 | 0.13 | 0.13 | 0.11 | 0.18 | 0.15 | 0.27 | 0.30 | 0.09 | 0.14 |
| Net Debt / EBITDA | 1.48 | 1.48 | 0.97 | 0.88 | 0.64 | 1.07 | 0.55 | 1.54 | 1.98 | 0.56 | 0.84 |
| Debt / FCF | — | 1.59 | 1.78 | 1.16 | 1.02 | 1.45 | 1.83 | 2.73 | 4.96 | 0.97 | 1.44 |
| Interest Coverage | 17.51 | 17.51 | 11.96 | 13.57 | 27.03 | 21.69 | 32.99 | 6.00 | 10.07 | 17.85 | 16.52 |
SNY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.09x means Sanofi can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.29x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.27x to 1.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | 1.09 | 1.46 | 1.27 | 1.42 | 1.44 | 1.75 | 1.40 | 1.41 | 1.70 | 1.62 |
| Quick Ratio | 0.29 | 0.29 | 1.14 | 0.87 | 1.05 | 1.03 | 1.32 | 1.01 | 0.98 | 1.26 | 1.20 |
| Cash Ratio | 0.27 | 0.27 | 0.27 | 0.36 | 0.53 | 0.47 | 0.72 | 0.48 | 0.40 | 0.67 | 0.63 |
| Asset Turnover | — | 0.37 | 0.33 | 0.33 | 0.32 | 0.33 | 0.33 | 0.33 | 0.32 | 0.36 | 0.33 |
| Inventory Turnover | 0.57 | 0.57 | 1.40 | 1.31 | 1.33 | 1.41 | 1.46 | 1.50 | 1.53 | 1.70 | 1.55 |
| Days Sales Outstanding | — | 3.10 | 87.60 | 96.82 | 96.70 | 91.19 | 97.22 | 97.80 | 95.61 | 87.42 | 95.21 |
SNY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sanofi returns 10.4% to shareholders annually — split between a 5.0% dividend yield and 5.4% buyback yield. A payout ratio of 58.7% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 5.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 5.0% | 3.9% | 3.9% | 3.6% | 3.4% | 3.2% | 3.2% | 3.1% | 3.5% | 3.4% | 3.6% |
| Payout Ratio | 58.7% | 58.7% | 84.6% | 82.5% | 49.8% | 64.4% | 32.0% | 139.2% | 87.6% | 44.1% | 79.8% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.4% | 4.2% | 4.5% | 4.3% | 6.6% | 5.0% | 10.1% | 2.3% | 4.0% | 7.8% | 4.5% |
| FCF Yield | 9.9% | 7.5% | 4.9% | 6.9% | 6.9% | 6.8% | 4.4% | 4.7% | 3.3% | 5.0% | 5.5% |
| Buyback Yield | 5.4% | 4.1% | 0.3% | 0.5% | 0.4% | 0.3% | 0.7% | 0.0% | 1.0% | 2.0% | 2.8% |
| Total Shareholder Yield | 10.4% | 8.0% | 4.1% | 4.0% | 3.8% | 3.5% | 3.9% | 3.1% | 4.5% | 5.4% | 6.4% |
| Shares Outstanding | — | $2.4B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.6B |
Peer Comparison
Compare SNY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SNYYou | $106B | 18.4 | 10.9 | 10.1 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 NVO | $154B | 12.7 | 7.5 | 17.3 | 81.0% | 41.4% | 58.4% | 34.9% | 0.9 |
 AZN | $287B | 28.3 | 16.0 | 24.4 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 NVS | $283B | 20.6 | 13.8 | 16.0 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 GSK | $102B | 6.7 | 8.4 | 12.8 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 BMY | $115B | 16.4 | 9.2 | 9.0 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 JNJ | $541B | 38.8 | 18.8 | 27.3 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Full SNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNY vs NVO
Side-by-side business, growth, and profitability comparison vs Novo Nordisk A/S.
Start ComparisonSNY — Frequently Asked Questions
Quick answers to the most common questions about buying SNY stock.
What is Sanofi's P/E ratio?
Sanofi's current P/E ratio is 18.4x. The historical average is 24.7x. This places it at the 25th percentile of its historical range.
What is Sanofi's EV/EBITDA?
Sanofi's current EV/EBITDA is 10.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.0x.
What is Sanofi's ROE?
Sanofi's return on equity (ROE) is 10.4%. The historical average is 12.7%.
Is SNY stock overvalued?
Based on historical data, Sanofi is trading at a P/E of 18.4x. This is at the 25th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Sanofi's dividend yield?
Sanofi's current dividend yield is 5.04% with a payout ratio of 58.7%.
What are Sanofi's profit margins?
Sanofi has 72.3% gross margin and 13.6% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Sanofi have?
Sanofi's Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.